Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results

Alnylam Pharmaceuticals (NASDAQ:ALNY) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60, FiscalAI reports. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.90 earnings per share.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• Q3 product revenue rose 52% year over year to approximately $1.3 billion, driven by AMVUTTRA and 59% growth in TTR revenue to $1.15 billion. Alnylam also ended the quarter with $3.6 billion in cash and marketable securities.
• Management expects 2026 TTR revenue at the low end of its $4.2 billion–$4.5 billion range, acknowledging that expanded commercial efforts have not yet translated into demand growth as quickly as anticipated. Potential fourth-quarter ordering volatility from the 340B rule and tighter UnitedHealth Medicare Advantage access may add pressure.
• Alnylam will expand the TRITON-CM study for nucresiran by 500 patients to approximately 2,250, primarily to account for potentially lower event rates as patients are diagnosed earlier and receive better background treatment. The company said the change is intended to improve statistical power and does not alter the expected ATTR cardiomyopathy launch timing of around 2030.
• Early brezosiran data in Huntington’s disease showed 60%–64% mean reductions in cerebrospinal-fluid mutant huntingtin, with reductions of up to 83% and no dose-dependent safety signals reported to date. Alnylam plans to advance the program toward a pivotal study in 2027, pending regulatory alignment.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $165.00 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm has a market capitalization of $22.08 billion, a P/E ratio of 8.57 and a beta of 0.28. The business’s 50-day moving average is $236.49 and its two-hundred day moving average is $286.19. Alnylam Pharmaceuticals has a 1 year low of $163.30 and a 1 year high of $479.79.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Sanford C. Bernstein lowered Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $376.00 to $199.00 in a research report on Friday. Jefferies Financial Group boosted their price objective on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a report on Tuesday, September 8th. BMO Capital Markets reissued an “outperform” rating and set a $290.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Needham & Company LLC lowered their target price on Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating for the company in a report on Thursday. Finally, JPMorgan Chase & Co. dropped their target price on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $317.95.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.